Thermo Fishr Sci Stock Price, News & Analysis

Thermo Fisher Scientific (NYSE: TMO) reported impressive financial results for Q4 and full year 2020, showing a 54% increase in Q4 revenue to $10.55 billion and a 26% rise in annual revenue to $32.22 billion. Q4 GAAP diluted EPS surged 151% to $6.24, while adjusted EPS increased 100% to $7.09. Strong growth driven by $3.2 billion in COVID-19 response revenue, alongside significant investments in innovation and infrastructure, supports a robust long-term growth strategy. The company also returned $1.8 billion in capital to shareholders through buybacks and dividends.

Thermo Fisher Scientific (NYSE: TMO) announced its acquisition of Mesa Biotech, a molecular diagnostic company, for approximately $450 million in cash, with the potential for an additional $100 million based on performance milestones. Mesa Biotech specializes in rapid PCR-based testing for infectious diseases, including COVID-19 and influenza, with revenues of about $45 million in 2020. The deal, aimed at enhancing Thermo Fisher's diagnostics portfolio, is expected to close in Q1 2021, pending regulatory approvals.

Thermo Fisher Scientific (TMO) announced the acquisition of Henogen S.A., Novasep's viral vector manufacturing business, for approximately €725 million. This strategic move aims to enhance Thermo Fisher's capabilities in cell and gene therapies, adding significant manufacturing capacity in Belgium. The Henogen business, recognized for its expertise and operational excellence, generated an estimated €80 million in revenue in 2020. The acquisition aligns with Thermo Fisher's mission to support global biotech clients and strengthens its position in the European market.

Thermo Fisher Scientific (NYSE: TMO) launched Managed Equipment Solutions, a subscription-based service that combines instrument procurement with essential support and services. This offering caters to biopharma companies, academic institutions, and healthcare organizations, aiming to enhance financial flexibility and operational efficiency.

Customers can bundle premium technologies with predictable costs, upgrading instruments every three to five years. The solution aims to reduce ownership costs and streamline the procurement process.

Thermo Fisher Scientific (NYSE: TMO) announced that CEO Marc N. Casper will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 p.m. (EDT). The presentation will cover the company's insights on the COVID-19 pandemic and future financial outlook. The webcast can be accessed through the Investors section of the company's website. Thermo Fisher has an annual revenue exceeding $25 billion and employs over 75,000 people globally.

Thermo Fisher Scientific (NYSE: TMO) will release its financial results for Q4 and full year 2020 before markets open on February 1, 2021. A conference call is scheduled for 8:30 a.m. EDT on the same day to discuss performance and future expectations. The company generated over $25 billion in annual revenue, serving a global customer base in life sciences, diagnostics, and laboratory productivity. For more details, visit thermofisher.com.

Thermo Fisher Scientific (NYSE: TMO) announced its intention to redeem approximately $2.6 billion of Senior Notes on January 15, 2021. This includes €0.5 billion of 2.150% Senior Notes due 2022, $1.0 billion of 3.000% Senior Notes due 2023, and $1.0 billion of 4.150% Senior Notes due 2024. The redemption price will be based on either the principal amount or the present value of remaining scheduled payments. Funding for this redemption will come from cash on hand. Thermo Fisher continues to lead in scientific innovation with annual revenues exceeding $25 billion.

Thermo Fisher Scientific (NYSE: TMO), a leader in serving science, will have CEO Marc N. Casper present virtually at the Evercore ISI HealthCONx Conference on December 1, 2020, at 1:00 p.m. (EST). The presentation will cover the company's insights regarding the impact of the COVID-19 pandemic and outline expectations for future financial performance. Thermo Fisher, with over $25 billion in annual revenue, aims to support customers in making the world healthier, cleaner, and safer. Access the live webcast on their website.

Thermo Fisher Scientific (NYSE: TMO) has appointed R. Alexandra "Alex" Keith to its board of directors, expanding the board to 13 members. Keith, CEO of Procter & Gamble's global Beauty business, oversees a $13 billion segment with 10,000 employees. This appointment is expected to strengthen Thermo Fisher's brand with customers worldwide. Marc N. Casper, CEO of Thermo Fisher, praised her leadership and innovation. Keith has been recognized as one of the "Fortune Most Powerful Women International" from 2018 to 2020.